197 related articles for article (PubMed ID: 15491164)
1. Recombinant EWS-FLI1 oncoprotein activates transcription.
Uren A; Tcherkasskaya O; Toretsky JA
Biochemistry; 2004 Oct; 43(42):13579-89. PubMed ID: 15491164
[TBL] [Abstract][Full Text] [Related]
2. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
[TBL] [Abstract][Full Text] [Related]
3. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
Uren A; Toretsky JA
Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
[TBL] [Abstract][Full Text] [Related]
4. The COOH-terminal domain of FLI-1 is necessary for full tumorigenesis and transcriptional modulation by EWS/FLI-1.
Arvand A; Welford SM; Teitell MA; Denny CT
Cancer Res; 2001 Jul; 61(13):5311-7. PubMed ID: 11431376
[TBL] [Abstract][Full Text] [Related]
5. Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo.
Aryee DN; Kreppel M; Bachmaier R; Uren A; Muehlbacher K; Wagner S; Breiteneder H; Ban J; Toretsky JA; Kovar H
Cancer Res; 2006 Oct; 66(20):9862-9. PubMed ID: 17047047
[TBL] [Abstract][Full Text] [Related]
6. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.
Lin PP; Brody RI; Hamelin AC; Bradner JE; Healey JH; Ladanyi M
Cancer Res; 1999 Apr; 59(7):1428-32. PubMed ID: 10197607
[TBL] [Abstract][Full Text] [Related]
7. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
Hahm KB; Cho K; Lee C; Im YH; Chang J; Choi SG; Sorensen PH; Thiele CJ; Kim SJ
Nat Genet; 1999 Oct; 23(2):222-7. PubMed ID: 10508522
[TBL] [Abstract][Full Text] [Related]
8. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A.
Toretsky JA; Erkizan V; Levenson A; Abaan OD; Parvin JD; Cripe TP; Rice AM; Lee SB; Uren A
Cancer Res; 2006 Jun; 66(11):5574-81. PubMed ID: 16740692
[TBL] [Abstract][Full Text] [Related]
9. EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene.
Thompson AD; Braun BS; Arvand A; Stewart SD; May WA; Chen E; Korenberg J; Denny C
Oncogene; 1996 Dec; 13(12):2649-58. PubMed ID: 9000139
[TBL] [Abstract][Full Text] [Related]
10. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
[TBL] [Abstract][Full Text] [Related]
11. EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage.
Ban J; Siligan C; Kreppel M; Aryee D; Kovar H
Adv Exp Med Biol; 2006; 587():41-52. PubMed ID: 17163154
[TBL] [Abstract][Full Text] [Related]
12. Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein.
Spahn L; Siligan C; Bachmaier R; Schmid JA; Aryee DN; Kovar H
Oncogene; 2003 Oct; 22(44):6819-29. PubMed ID: 14534527
[TBL] [Abstract][Full Text] [Related]
13. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.
Im YH; Kim HT; Lee C; Poulin D; Welford S; Sorensen PH; Denny CT; Kim SJ
Cancer Res; 2000 Mar; 60(6):1536-40. PubMed ID: 10749119
[TBL] [Abstract][Full Text] [Related]
14. A molecular function map of Ewing's sarcoma.
Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H
PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404
[TBL] [Abstract][Full Text] [Related]
15. A polypeptide from the junction region sequence of EWS-FLI1 inhibits Ewing's sarcoma cells, interacts with the EWS-FLI1 and partner proteins.
Thangaretnam KP; Gopisetty G; Ramanathan P; Rajkumar T
Sci Rep; 2017 Aug; 7(1):7172. PubMed ID: 28775288
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
[TBL] [Abstract][Full Text] [Related]
17. EWS-FLI1 causes neuroepithelial defects and abrogates emigration of neural crest stem cells.
Coles EG; Lawlor ER; Bronner-Fraser M
Stem Cells; 2008 Sep; 26(9):2237-44. PubMed ID: 18556509
[TBL] [Abstract][Full Text] [Related]
18. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma.
Ban J; Bennani-Baiti IM; Kauer M; Schaefer KL; Poremba C; Jug G; Schwentner R; Smrzka O; Muehlbacher K; Aryee DN; Kovar H
Cancer Res; 2008 Sep; 68(17):7100-9. PubMed ID: 18757425
[TBL] [Abstract][Full Text] [Related]
19. Participation of nuclear localization signal 2 in the 3'-ETS domain of FLI1 in nuclear translocation of various chimeric EWS-FLI1 oncoproteins in Ewing tumor.
Honsei N; Ikuta T; Kawana K; Kaneko Y; Kawajiri K
Int J Oncol; 2006 Sep; 29(3):689-93. PubMed ID: 16865286
[TBL] [Abstract][Full Text] [Related]
20. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
Kinsey M; Smith R; Lessnick SL
Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
